KUALA LUMPUR: Pharmaniaga Bhd’s earnings plunged 92.8 per cent in the third quarter, dragged by higher transportation costs for delivering new products to East Malaysia via air and sea.
Net profit for the quarter ended Sept 30, 2025 fell to RM7.28 million from RM101 million previously, while revenue slipped 2.19 per cent to RM1 billion from RM1.03 billion, the group’s filing with Bursa Malaysia showed.
For the nine-month period, net profit dropped 68.48 per cent to RM40.8 million from RM129 million, although revenue rose 5.52 per cent to RM2.99 billion from RM2.83 billion, supported by stronger demand in the concession segment.
Despite the weaker results, managing director Datuk Zulkifli Jafar said the healthcare sector remains promising, noting that the 2026 Budget has provided renewed optimism for the industry.
He said the group expects higher allocations for medical supplies and concession operations, reinforcing a positive outlook for both concession and non-concession businesses.
He also said Pharmaniaga continued to make meaningful headway in the biopharmaceutical segment, with new revenue stream surpassing RM10 million across five vaccine products and the insulin localisation programme on track.
“The pharmaceutical division remains active with new product launches and approvals, with the inclusion of 160 new products to the approved products purchase list, bringing to a total of more than 840 products during the year.
“In addition, five new generic products were launched and twelve product approvals secured to date in 2025, further strengthening the group’s pharmaceutical pipeline,” he said.
Zulkifli said the logistics and distribution arm recorded a 14.5 per cent increase in volume sold for the nine-month period, reflecting stronger demand across the group’s supply network.
To cater for the increase in volume and higher operational activity, Pharmaniaga continues to optimise costs through digitalisation and operational improvements.
“In Indonesia, our 37th distribution outlet in Palu and the Contract Development and Manufacturing Organisation partnership with a leading pharmacy chain signal strong regional growth momentum.
“With these encouraging developments, Pharmaniaga remains focused on strengthening its core business, expanding biopharmaceutical capabilities and driving sustainable growth across all markets,” he said.
© New Straits Times Press (M) Bhd
